Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin K Inhibitor) in the Treatment of Postmenopausal Women With Osteoporosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Odanacatib (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms Cat-K 11b
- Sponsors Merck Sharp & Dohme
- 17 Apr 2020 Results (n=1280) of pooled analysis from phase 1 (P005, P025, and P014), phase 2b (P004 and P022), and phase 3 (P018) , assessing population pharmacokinetic (PK) model in postmenopausal women for odanacatib, published in the Journal of Clinical Pharmacology
- 05 Apr 2014 Results of an analysis from the 5-year extension phase presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
- 03 Nov 2012 Planned number of patients changed from 246 to 375 as reported by European Clinical Trials Database.